Validation of a Mouse Model of Pancreatic Carcinogenesis
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 7/11/2015 |
| Start Date: | March 2009 |
| End Date: | May 2013 |
| Contact: | Wendy K Chung, MD |
| Email: | wkc15@columbia.edu |
BRCA1 and BRCA2 Genetic Mutations in Mucinous Versus Nonmucinous Precursor Lesions of the Pancreas: Validation of a Mouse Model of Pancreatic Carcinogenesis
The primary aim of this study is to determine if mutations of BRCA1 and BRCA2 result in
different precancerous pathways to pancreatic ductal adenocarcinoma (PDAC), as suggested in
our validated mouse model. Genomic DNA will be isolated on normal tissue obtained from
patients who underwent pancreatic resection for PDAC, intraductal papillary mucinous
neoplasm (IPMN) or mucinous cystic neoplasm (MCN). Tissue will be examined for the three
most common founder mutations in Ashkenazi Jews. In the cases in which BRCA1 or BRCA2
mutations are found, heterozygote normal and abnormal tissue will be examined to look for
mutations in the other BRCA1 or BRCA2 allele. The interaction between other cancer causing
genes with BRCA1/2 will also be evaluated by comparing the sequences of the other genes in
pre-cancerous lesions.
We hypothesize that BRCA1- and BRCA2-mediated pancreatic ductal adenocarcinoma progresses
through the PanIN route, as seen in both BRCA1 and BRCA2 murine models of pancreatic cancer.
We further hypothesize that BRCA1 mutations may enable an additional pre- neoplastic pathway
through MCN, and that IPMN may embody yet another pre- neoplastic pathway.
different precancerous pathways to pancreatic ductal adenocarcinoma (PDAC), as suggested in
our validated mouse model. Genomic DNA will be isolated on normal tissue obtained from
patients who underwent pancreatic resection for PDAC, intraductal papillary mucinous
neoplasm (IPMN) or mucinous cystic neoplasm (MCN). Tissue will be examined for the three
most common founder mutations in Ashkenazi Jews. In the cases in which BRCA1 or BRCA2
mutations are found, heterozygote normal and abnormal tissue will be examined to look for
mutations in the other BRCA1 or BRCA2 allele. The interaction between other cancer causing
genes with BRCA1/2 will also be evaluated by comparing the sequences of the other genes in
pre-cancerous lesions.
We hypothesize that BRCA1- and BRCA2-mediated pancreatic ductal adenocarcinoma progresses
through the PanIN route, as seen in both BRCA1 and BRCA2 murine models of pancreatic cancer.
We further hypothesize that BRCA1 mutations may enable an additional pre- neoplastic pathway
through MCN, and that IPMN may embody yet another pre- neoplastic pathway.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of death from malignancy
in the United States. Several gene mutations and cancer syndromes have been identified that
are found in greater frequency in individuals with PDAC, including the breast ovary cancer
syndrome (BRCA1 and BRCA2 mutations). We have recently generated mouse models of pancreatic
cancer in which we found that deletions of either BRCA1 or BRCA2 cooperate with K-ras
activation and p53 mutations to increase the rate of tumorigenesis via accelerated
progression of Pancreatic Intraepithelial Neoplasia (PanIN). However, only BRCA1 deletions
were associated with the development of concomitant Mucinous Cystic Neoplasms (MCNs),
suggesting potentially distinct pathways for BRCA1- and BRCA2-mediated tumorigenesis in the
pancreas. Our primary aim is to determine if germline mutations of BRCA1 and BRCA2 result in
different pre-neoplastic pathways to pancreatic cancer, as in our murine model. Genomic DNA
will be isolated on normal tissue obtained from patients who underwent pancreatic resection
for pancreatic cancer, IPMN or MCN. Tissue will be genotyped for the three most common
founder mutations in Ashkenazi Jews. In the cases in which BRCA1 or BRCA2 mutations are
found, heterozygote normal and abnormal tissue will be microdissected to look for loss of
heterozygosity at the BRCA1 or BRCA2 allele. Our secondary aim is to evaluate the
interaction of p53 and Kras with BRCA1 and BRCA2 by sequencing p53 and Kras in PanIN as
compared to IPMN and MCN lesions.
in the United States. Several gene mutations and cancer syndromes have been identified that
are found in greater frequency in individuals with PDAC, including the breast ovary cancer
syndrome (BRCA1 and BRCA2 mutations). We have recently generated mouse models of pancreatic
cancer in which we found that deletions of either BRCA1 or BRCA2 cooperate with K-ras
activation and p53 mutations to increase the rate of tumorigenesis via accelerated
progression of Pancreatic Intraepithelial Neoplasia (PanIN). However, only BRCA1 deletions
were associated with the development of concomitant Mucinous Cystic Neoplasms (MCNs),
suggesting potentially distinct pathways for BRCA1- and BRCA2-mediated tumorigenesis in the
pancreas. Our primary aim is to determine if germline mutations of BRCA1 and BRCA2 result in
different pre-neoplastic pathways to pancreatic cancer, as in our murine model. Genomic DNA
will be isolated on normal tissue obtained from patients who underwent pancreatic resection
for pancreatic cancer, IPMN or MCN. Tissue will be genotyped for the three most common
founder mutations in Ashkenazi Jews. In the cases in which BRCA1 or BRCA2 mutations are
found, heterozygote normal and abnormal tissue will be microdissected to look for loss of
heterozygosity at the BRCA1 or BRCA2 allele. Our secondary aim is to evaluate the
interaction of p53 and Kras with BRCA1 and BRCA2 by sequencing p53 and Kras in PanIN as
compared to IPMN and MCN lesions.
Inclusion Criteria:
- Tissue-confirmed diagnosis of pancreatic adenocarcinoma, MCN, or IPMN.
- Underwent surgical resection for pancreatic adenocarcinoma, MCN, or IPMN.
Exclusion Criteria:
- Unwilling to provide informed consent.
- Under the age of 18.
We found this trial at
1
site
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
Click here to add this to my saved trials
